Dana-Farber Cancer Institute shared a post on LinkedIn:
“We’re proud to announce a new strategic collaboration with OncoClinic, a joint venture between Al-Faisaliah Group (JSC) and OncoclínicasandCo, to bring advanced and personalized oncology to Saudi Arabia.
Through this collaboration, we’ll serve as academic advisor to OncoClinic, providing strategic planning support, clinical program development advice, and robust interdisciplinary clinician education programs. This collaboration will expand precision oncology practices, evidence-based treatments, and a patient-centered approach aligned with the highest international standards for patients in the kingdom.
‘We are honored to collaborate with OncoClinic to bring world-class oncology care closer to patients and their families across the Kingdom of Saudi Arabia. Consistent with our international mission, this new collaboration will have a significant impact on patients, clinicians, and the broader healthcare community in Saudi Arabia,’ said Craig A Bunnell, Morse Family Chief Medical Officer at Dana-Farber and Associate Professor of Medicine at Harvard Medical School.
A leadership delegation from Dana-Farber traveled to Riyadh to officially kick off the collaboration, with a program that included remarks from Toni Choueiri, Division Chief of GU Oncology and Medical Director of International Strategic Initiatives and Otto Metzger, Associate Medical Director of International Strategic Initiatives, as well as Mohammed Alotaibi of OncoClinic.”
Katya Losk, Senior Director of International Strategic Initiatives at Dana-Farber Cancer Institute, shared Dana-Farber Cancer Institute’s post, adding:
“Thrilled to be part of this new strategic collaboration to enhance access to personalized cancer care across Saudi Arabia. Thank you to our friends and colleagues at OncoClinic for your warm hospitality.”
More posts featuring Dana-Farber Cancer Institute on OncoDaily.